Anvesana develops therapies for treating inheritable blood and bleeding disorders.
Anvesana has raised $250K in total funding. The most recent round was Seed. The last funding was announced in September 2023.
Anvesana's investors include Pathway to Cures.
Anvesana is headquartered in New York, United States.
Anvesana develops therapies for treating inheritable blood and bleeding disorders.
Anvesana is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Anvesana — Funding & Investors." VCBacked, September 5, 2023, https://www.vcbacked.co/company/anvesana. Accessed August 16, 2026.
VCBacked. (2023). Anvesana — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/anvesana
{{cite web |title=Anvesana — Funding & Investors |url=https://www.vcbacked.co/company/anvesana |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated